Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) Target Price at $17.39

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $17.39.

ROIV has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Piper Sandler lifted their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th.

Insider Activity

In related news, CAO Rakhi Kumar sold 250,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CAO Rakhi Kumar sold 250,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew Gline sold 1,983,257 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the transaction, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,577,309 shares of company stock valued at $42,151,184. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in Roivant Sciences in the second quarter worth approximately $34,000. Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences during the second quarter worth $36,000. Quarry LP purchased a new position in shares of Roivant Sciences during the second quarter worth $53,000. Acadian Asset Management LLC purchased a new position in shares of Roivant Sciences during the first quarter worth $72,000. Finally, Fifth Third Wealth Advisors LLC purchased a new position in shares of Roivant Sciences during the second quarter worth $101,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $11.80 on Friday. Roivant Sciences has a 52 week low of $8.24 and a 52 week high of $13.06. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $8.72 billion, a PE ratio of 2.33 and a beta of 1.24. The stock’s 50-day moving average price is $11.80 and its 200-day moving average price is $11.23.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same period last year, the firm earned ($0.38) EPS. The company’s quarterly revenue was up 155.1% on a year-over-year basis. As a group, equities analysts expect that Roivant Sciences will post -1.14 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.